Skip to content

Outcome Study of Double Bare Stent for Malignant Gastric Outlet Obstruction

Phase IV Study of Double Bare Self-expandable Metallic Stent for Malignant Gastric Outlet Obstruction

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02156505
Enrollment
49
Registered
2014-06-05
Start date
2013-01-31
Completion date
2015-07-31
Last updated
2014-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Outlet Obstruction Due to Malignancy

Keywords

stent, gastric outlet obstruction, restenosis

Brief summary

Self-expandable metallic stents provide effective palliation of malignant gastric outlet obstruction. However, uncovered stent are often associated with re-stenosis caused by tumor in-growth through the stent mesh. The Self-expandable metallic stents which has the design of smaller wire mesh size (double bare stent) were developed and used in Korea. This new design was developed to minimize the re-stenosis of uncovered stent, but the outcome is unknown. The end point of this study is the 8-weeks patency rate after placement of double bare as well as technical and clinical success rates.

Interventions

PROCEDUREplacement of double bare stent
DEVICEDoubleBare stent

Sponsors

Stent research group, Korean Society of Gastrointestinal Endoscopy, Korea
CollaboratorUNKNOWN
National Cancer Center, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Malignant gastric outlet obstruction * Symptoms compatible with gastric outlet obstruction * An inoperable condition because of extent of disease or patient's conditions

Exclusion criteria

* History of enteral stent placement, undergone gastric surgery. * Additional small bowel stenosis distal to gastric outlet obstruction. * Refuse to be enrolled to study.

Design outcomes

Primary

MeasureTime frame
The patency rate at 8 weeks after placement.8 weeks

Secondary

MeasureTime frame
Technical and clinical success ratesup to 8 weeks
re-stenosis rate8 weeks
migration rate8 weeks

Countries

South Korea

Contacts

Primary ContactChan G Kim, M.D.
glse@chol.com+82-31-920-1620

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026